In vitro effect of Dovitinib (TKI258), a multi-target angiokinase inhibitor on aggressive meningioma cells.
CONCLUSIONS: This study establishes the groundwork for development of Dovitinib as a therapeutic agent for high-grade AM with either frequent codeletion or mutated CHEK2 and NF2, an avenue with high translational potential.
PMID: 32441531 [PubMed - as supplied by publisher]
Source: Cancer Investigation - Category: Cancer & Oncology Tags: Cancer Invest Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Chemotherapy | Gastroschisis Repair | Genetics | Men | Neurofibromatosis | Neurology | Neurosurgery | Study